UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 189

Sortiert nach

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease

Circulation (New York, N.Y.), 2012-11, Vol.126 (19), p.2283-2292

2012

Volltextzugriff (PDF)

A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects

Journal of clinical pharmacology, 2017-05, Vol.57 (5), p.627-639

2017

Volltextzugriff (PDF)

Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry

BMC neurology, 2019-05, Vol.19 (1), p.84-84, Article 84

2019

Volltextzugriff (PDF)

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

European heart journal, 2012-05, Vol.33 (9), p.1142-1149

2012

Volltextzugriff (PDF)

Assessing the ability of boys with Duchenne muscular dystrophy age 4–7 years to swallow softgel capsules: Clinical trial experience with edasalonexent

Journal of clinical pharmacy and therapeutics, 2022-01, Vol.47 (1), p.33-37

2022

Volltextzugriff (PDF)

Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial

Neuromuscular disorders : NMD, 2021-05, Vol.31 (5), p.385-396

2021

Volltextzugriff (PDF)

A Mixed-Method Study Exploring Patient-Experienced and Caregiver-Reported Benefits and Side Effects of Corticosteroid Use in Duchenne Muscular Dystrophy

Journal of neuromuscular diseases, 2023-01, Vol.10 (4), p.593-613

2023

Volltextzugriff (PDF)

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia

Journal of clinical lipidology, 2015-03, Vol.9 (2), p.201-209

2015

Volltextzugriff (PDF)

Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy

Journal of neuromuscular diseases, 2019-01, Vol.6 (1), p.43-54

2019

Volltextzugriff (PDF)

Dietary sphingomyelin suppresses intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers

Gastroenterology (New York, N.Y. 1943), 2002-04, Vol.122 (4), p.948-956

2002

Volltextzugriff (PDF)

Phase 1 Multiple Ascending Dose Study of CAT-2054, a Novel Oral Sterol Regulatory Element Binding Protein Inhibitor

Journal of clinical lipidology, 2016-05, Vol.10 (3), p.715-716

2016

Volltextzugriff (PDF)

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

Atherosclerosis, 2001-10, Vol.158 (2), p.407-416

2001

Volltextzugriff (PDF)

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

The American journal of medicine, 2001-04, Vol.110 (5), p.352-360

2001

Volltextzugriff (PDF)

Phase 1 Study of CAT-2054, an Oral Novel Modulator of SREBP

Journal of clinical lipidology, 2015-05, Vol.9 (3), p.474-475

2015

Volltextzugriff (PDF)

Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial

Mayo Clinic proceedings, 2001-10, Vol.76 (10), p.971-982

2001

Volltextzugriff (PDF)

CAT-2003, an Analog of CAT-2054 and a Novel Oral SREBP Inhibitor, Inhibits Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis

Journal of clinical lipidology, 2016-05, Vol.10 (3), p.722-723

2016

Volltextzugriff (PDF)

Protecting and Preserving Dystrophic Muscle: The Balance Between Exercise and Contraction-Induced Muscle Injury

European Medical Journal (Chelmsford, England), 2024-06, p.23-30

2024

Volltextzugriff (PDF)

A 50-Week Extension Study on the Safety and Efficacy of Colesevelam in Adults with Primary Hypercholesterolemia

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010-01, Vol.10 (5), p.305-314

2010

Volltextzugriff (PDF)

The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons

The Journal of general physiology, 1995-07, Vol.106 (1), p.67-84

1995

Volltextzugriff (PDF)

Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Decreases Postprandial Triglycerides

Journal of clinical lipidology, 2014-05, Vol.8 (3), p.311-311

2014

Volltextzugriff (PDF)

Enabling Field Asymmetric Ion Mobility Spectrometry Separation of Fentanyl-Related Compounds Using Controlled Humidity

Analytical chemistry (Washington), 2020-02, Vol.92 (4), p.2917-2921

2020

Volltextzugriff (PDF)

Preclinical and Clinical Development of Deferitrin, a Novel, Orally Available Iron Chelator

Annals of the New York Academy of Sciences, 2005-01, Vol.1054 (1), p.492-494

2005

Volltextzugriff (PDF)

Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia

Clinical cardiology (Mahwah, N.J.), 2001-06, Vol.24 (6), p.467-474

2001

Volltextzugriff (PDF)

Colesevelam HCl Improves Fasting Plasma Glucose and Lipid Levels in Patients with Prediabetes

Postgraduate medicine, 2009-11, Vol.121 (6), p.62-69

2009

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(159)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(189)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease

A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects

Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

Assessing the ability of boys with Duchenne muscular dystrophy age 4–7 years to swallow softgel capsules: Clinical trial experience with edasalonexent

Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial

A Mixed-Method Study Exploring Patient-Experienced and Caregiver-Reported Benefits and Side Effects of Corticosteroid Use in Duchenne Muscular Dystrophy

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia

Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy

Dietary sphingomyelin suppresses intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers

Phase 1 Multiple Ascending Dose Study of CAT-2054, a Novel Oral Sterol Regulatory Element Binding Protein Inhibitor

A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

Phase 1 Study of CAT-2054, an Oral Novel Modulator of SREBP

Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial

CAT-2003, an Analog of CAT-2054 and a Novel Oral SREBP Inhibitor, Inhibits Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis

Protecting and Preserving Dystrophic Muscle: The Balance Between Exercise and Contraction-Induced Muscle Injury

A 50-Week Extension Study on the Safety and Efficacy of Colesevelam in Adults with Primary Hypercholesterolemia

The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons

Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Decreases Postprandial Triglycerides

Enabling Field Asymmetric Ion Mobility Spectrometry Separation of Fentanyl-Related Compounds Using Controlled Humidity

Preclinical and Clinical Development of Deferitrin, a Novel, Orally Available Iron Chelator

Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia

Colesevelam HCl Improves Fasting Plasma Glucose and Lipid Levels in Patients with Prediabetes

Suchergebnisse filtern